Title |
A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
|
---|---|
Published in |
Frontiers in Molecular Neuroscience, January 2018
|
DOI | 10.3389/fnmol.2017.00447 |
Pubmed ID | |
Authors |
Karima Schwab, Silke Frahm, David Horsley, Janet E. Rickard, Valeria Melis, Elizabeth A. Goatman, Mandy Magbagbeolu, Morag Douglas, Michael G. Leith, Thomas C. Baddeley, John M. D. Storey, Gernot Riedel, Claude M. Wischik, Charles R. Harrington, Franz Theuring |
Abstract |
α-Synuclein (α-Syn) aggregation is a pathological feature of synucleinopathies, neurodegenerative disorders that include Parkinson's disease (PD). We have tested whether N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(hydromethanesulfonate) (leuco-methylthioninium bis(hydromethanesulfonate); LMTM), a tau aggregation inhibitor, affects α-Syn aggregation in vitro and in vivo. Both cellular and transgenic models in which the expression of full-length human α-Syn (h-α-Syn) fused with a signal sequence peptide to promote α-Syn aggregation were used. Aggregated α-Syn was observed following differentiation of N1E-115 neuroblastoma cells transfected with h-α-Syn. The appearance of aggregated α-Syn was inhibited by LMTM, with an EC50 of 1.1 μM, with minimal effect on h-α-Syn mRNA levels being observed. Two independent lines of mice (L58 and L62) transgenic for the same fusion protein accumulated neuronal h-α-Syn that, with aging, developed into fibrillary inclusions characterized by both resistance to proteinase K (PK)-cleavage and their ability to bind thiazin red. There was a significant decrease in α-Syn-positive neurons in multiple brain regions following oral treatment of male and female mice with LMTM administered daily for 6 weeks at 5 and 15 mg MT/kg. The early aggregates of α-Syn and the late-stage fibrillar inclusions were both susceptible to inhibition by LMTM, a treatment that also resulted in the rescue of movement and anxiety-related traits in these mice. The results suggest that LMTM may provide a potential disease modification therapy in PD and other synucleinopathies through the inhibition of α-Syn aggregation. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 25% |
Student > Master | 7 | 15% |
Student > Bachelor | 6 | 13% |
Unspecified | 2 | 4% |
Professor | 2 | 4% |
Other | 5 | 10% |
Unknown | 14 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 9 | 19% |
Agricultural and Biological Sciences | 4 | 8% |
Chemistry | 4 | 8% |
Medicine and Dentistry | 4 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Other | 8 | 17% |
Unknown | 16 | 33% |